Associated Papers
Clinical significance of FBXW7 loss of function in human cancers.
Fan J et al.
Molecular Cancer, 2022
Somatic Evolution in Non-neoplastic IBD-Affected Colon.
Olafsson S et al.
Cell, 2020
32697969 (PubMed )
Supplement: mmc4.xlsx › B__Driver_candidates
Targeted next generation sequencing identified clinically actionable mutations in patients with esophageal sarcomatoid carcinoma.
Lu H et al.
Bmc Cancer, 2018
Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.
Santarpia L et al.
Breast Cancer Research and Treatment, 2012
The structural impact of cancer-associated missense mutations in oncogenes and tumor suppressors.
Stehr H et al.
Molecular Cancer, 2011
21575214 (PubMed )
Supplement: 1476-4598-10-54-S3.XLS › mutations.txt
FBXW7/hCDC4 is a general tumor suppressor in human cancer.
Akhoondi S et al.
Cancer Research, 2007
BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets.
Calhoun ES et al.
The American Journal of Pathology, 2003
Select a paper to view details